Stryker Corporation $SYK Stock Acquired by Provenance Wealth Advisors LLC

Posted by Brian Himes on Nov 5th, 2026

Provenance Wealth Advisors LLC raised its holdings in Stryker Corporation (NYSE:SYK – Free Report) by 1,376.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,455 shares of the medical technology company’s stock after acquiring an additional 3,221 shares during the quarter. Provenance Wealth Advisors LLC’s holdings in Stryker were worth $951,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Community Bank & Trust Waco Texas raised its position in shares of Stryker by 2.3% during the second quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock worth $439,000 after purchasing an additional 31 shares during the period. Cornerstone Financial Management LLC lifted its holdings in shares of Stryker by 66.0% during the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. NWF Advisory Services Inc. boosted its position in shares of Stryker by 2.3% in the 2nd quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock valued at $463,000 after purchasing an additional 33 shares during the period. Harold Davidson & Associates Inc. boosted its position in shares of Stryker by 0.4% in the 1st quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock valued at $2,848,000 after purchasing an additional 34 shares during the period. Finally, Private Harbour Investment Management & Counsel LLC increased its stake in Stryker by 0.9% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 3,927 shares of the medical technology company’s stock worth $1,236,000 after purchasing an additional 34 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 9.6%

Shares of NYSE SYK opened at $340.39 on Thursday. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. Stryker Corporation has a one year low of $267.00 and a one year high of $389.33. The business has a 50-day moving average price of $292.21 and a two-hundred day moving average price of $323.91. The firm has a market capitalization of $129.59 billion, a PE ratio of 36.25, a PEG ratio of 2.13 and a beta of 0.78.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to analysts’ expectations of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company’s revenue was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.19 earnings per share. As a group, analysts predict that Stryker Corporation will post 14.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on SYK shares. Needham & Company LLC cut their price objective on Stryker from $418.00 to $359.00 and set a “buy” rating on the stock in a report on Friday, October 30th. TD Cowen decreased their target price on shares of Stryker from $298.00 to $290.00 and set a “hold” rating for the company in a report on Friday, October 30th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Stryker from $315.00 to $275.00 and set a “hold” rating on the stock in a research report on Friday, October 30th. Barclays cut their price target on shares of Stryker from $375.00 to $365.00 and set an “overweight” rating on the stock in a report on Friday, October 30th. Finally, Truist Financial restated a “hold” rating and issued a $305.00 price target (down from $310.00) on shares of Stryker in a research report on Monday. Twenty-one investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $343.73.

View Our Latest Stock Report on Stryker

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda Stryker sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 351,267 shares of company stock worth $118,197,701 over the last ninety days. 4.60% of the stock is currently owned by insiders.

Stryker Company Profile

(Free Report)

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.